| Title |
Pharmacokinetics and tolerability of oral cannabis preparations in patients with medication overuse headache (MOH)—a pilot study
|
|---|---|
| Published in |
European Journal of Clinical Pharmacology, July 2018
|
| DOI | 10.1007/s00228-018-2516-3 |
| Pubmed ID | |
| Authors |
Lanfranco Pellesi, Manuela Licata, Patrizia Verri, Daniele Vandelli, Federica Palazzoli, Filippo Marchesi, Maria Michela Cainazzo, Luigi Alberto Pini, Simona Guerzoni |
| Abstract |
The recent release of a medical cannabis strain has given a new impulse for the study of cannabis in Italy. The National Health Service advises to consume medical cannabis by vaporizing, in decoction or oil form. This is the first study that explores the pharmacokinetics and tolerability of a single oral dose of cannabis as decoction (200 ml) or in olive oil (1 ml), as a first step to improve the prescriptive recommendations. This is a single-center, open-label, two-period crossover study designed to assess the pharmacokinetics and tolerability of oral cannabis administered to 13 patients with medication overuse headache (MOH). A liquid chromatography tandem-mass spectrometry (LC-MS/MS) method was conducted for the quantification of THC, CBD, 11-OH-THC, THC-COOH, THC-COOH-glucuronide, THCA-A, and CBDA. Blood pressure, heart rate, and a short list of symptoms by numerical rating scale (NRS) were assessed. Decoctions of cannabis showed high variability in cannabinoids content, compared to cannabis oil. For both preparations, THCA-A and CBDA were the most widely absorbed cannabinoids, while THC and CBD were less absorbed. The most important differences concern the bioavailability of THC, higher in oil (AUC0-24 7.44, 95% CI 5.19, 9.68) than in decoction (AUC0-24 3.34, 95% CI 2.07, 4.60), and the bioavailability of CBDA. No serious adverse events were reported. Cannabis decoction and cannabis oil showed different pharmacokinetic properties, as well as distinct consequences on patients. This study was performed in a limited number of patients; future studies should be performed to investigate the clinical efficacy in larger populations. |
Mendeley readers
The data shown below were compiled from readership statistics for 118 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 118 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 22 | 19% |
| Student > Bachelor | 12 | 10% |
| Student > Master | 10 | 8% |
| Other | 9 | 8% |
| Student > Ph. D. Student | 8 | 7% |
| Other | 13 | 11% |
| Unknown | 44 | 37% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 20 | 17% |
| Pharmacology, Toxicology and Pharmaceutical Science | 17 | 14% |
| Biochemistry, Genetics and Molecular Biology | 8 | 7% |
| Agricultural and Biological Sciences | 4 | 3% |
| Psychology | 4 | 3% |
| Other | 15 | 13% |
| Unknown | 50 | 42% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 18 December 2019.
All research outputs
#17,632,616
of 25,844,183 outputs
Outputs from European Journal of Clinical Pharmacology
#2,197
of 2,777 outputs
Outputs of similar age
#222,677
of 342,298 outputs
Outputs of similar age from European Journal of Clinical Pharmacology
#20
of 31 outputs
Altmetric has tracked 25,844,183 research outputs across all sources so far. This one is in the 21st percentile – i.e., 21% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,777 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.5. This one is in the 15th percentile – i.e., 15% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 342,298 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 26th percentile – i.e., 26% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 31 others from the same source and published within six weeks on either side of this one. This one is in the 25th percentile – i.e., 25% of its contemporaries scored the same or lower than it.